Centre and states need to work in tandem and in a collaborative spirit as was done during the previous surges for COVID-19 prevention and management
The two-day event focused on the multi-faceted relationship of clinical research stakeholders and looked at bridging the academic and clinical research gap.
Phase-III trials were conducted for safety, and immunogenicity in around 3,100 subjects, in 14 trial sites across India (supported by BIRAC)
If approved, TAK-003 has the potential to become an important dengue prevention option for healthcare providers
Program will fight the rising incidence of antimicrobial (drug) resistance and improve patient outcomes
The core of “LANXESS Biosecurity Solutions” is a portfolio of scientifically formulated, highly effective and versatile biocidal products
CEPI will provide up to US$40 million in initial funding to support the development of mRNA-vaccine candidates against Lassa Fever virus
This recognition marks the third time in five years that Merck has been included on Fortune’s Change the World list.
The Coalition for Epidemic Preparedness Innovations (CEPI) has recently partnered with the consortium of India-based Bharat Biotech, University of Sydney and ExcellGene to develop “variantproof” COVID-19 vaccine.
Ours is a story of India’s resilient public health system and of everyone working together as team India to battle the pandemic
Subscribe To Our Newsletter & Stay Updated
